According to the recently published ICOS 2003 Corporate Report: We completed patient follow-up in a Phase 2 clinical study evaluating RTX(TM) (resiniferatoxin) for the treatment of interstitial cystitis. In late January 2004, it was determined that RTX was not effective in relieving patients' symptoms. We will not pursue additional studies of interstitial cystitis.
www.icos.com
www.icos.com
Comment